Cardiology

Back to articles

Risk of CV events reduced with a PCSK9 inhibitor

KEY POINT

Addition of evolocumab (Repatha—Amgen) to statin background therapy in patients with a history of atherosclerotic cardiovascular disease (ASCVD) resulted in significant reductions in LDL cholesterol levels and reduced the risk of cardiovascular (CV) events, according to results of the landmark FOURIER trial published online in the New England Journal of Medicine.

SOURCES

Sabatine MS, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;[Epub ahead of print].

Dullaart RPF. PCSK9 inhibition to reduce cardiovascular events. N Engl J Med. 2017;[Epub ahead of print].